MHRA confirms acceptance of UK Marketing Authorisation Application for HMTM
We’re pleased to announce the Medicines and Healthcare products Regulatory Agency (MHRA) has confirmed acceptance of the UK Marketing Authorisation Application (MAA) for hydromethylthionine mesylate (HMTM), a 4 mg oral tablet for the treatment of mild cognitive impairment (MCI-AD) and mild to moderate Alzheimer’s disease.
This application is being reviewed within the scope of the 150-day accelerated assessment procedure, which is used by MHRA to accelerate the availability of medicines for patients in the UK.
We look forward to sharing further updates as the application progresses.
Recent News
TauRx Pharmaceuticals Ltd, a global leader in tau-based research in Alzheimer’s disease (AD), has announced the submission of a UK Marketing Authorisation Application (MAA) for hydromethylthionine mesylate (HMTM) for treatment of mild cognitive impairment (MCI-AD) and mild to moderate stages of dementia due to Alzheimer’s disease.
Jul 01, 2024
TauRx Pharmaceuticals Ltd., a global leader in tau-based research in Alzheimer’s disease (AD), presented the 24-month data from its Phase 3 LUCIDITY trial of hydromethylthionine mesylate (HMTM) at the AD/PD™ 2024 Alzheimer's & Parkinson's Diseases Conference in Lisbon, Portugal.
Mar 07, 2024
Today is the United Nations International Day of Women and Girls in Science. The day is marked every year on February 11 to ensure equal access and participation for women and girls in science.
Feb 11, 2024
TauRx announces it will present the 24-month data from its Phase III LUCIDITY trial at the upcoming AD/PD™ 2024 Alzheimer's & Parkinson's Diseases Conference from 5-9 March 2024, in Lisbon, Portugal.
Feb 06, 2024